SANOFI has entered into an agreement to acquire Vicebio, a company formed in 2018 to develop the University of Queensland's proprietary Molecular Clamp technology to make vaccines against life-threatening respiratory viral infections.
The US$1.6 billion (A$2.4 billion) deal is the largest involving a company that is commercialising intellectual property from an Australian university, and represents an opportunity for the technology to be accelerated through the final stages of translation into a vaccine to address global health challenges.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jul 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jul 25
